Press releases

Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company’s ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective therapy in patients undergoing open-heart surgery.

Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial, POINTER, which is evaluating the kidney-protective effects of the drug candidate RMC-035 in connection with open-heart surgery. The company...

Guard Therapeutics (publ) today announced that the design of its ongoing Phase 2b clinical trial, POINTER, will be presented at the annual congress of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) in Vienna, Austria.

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announced that the number of shares and votes in the Company has changed due to the recently completed Rights Issue (for further information, see the Company’s press release on April 4, 2025).

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION...